10-Q · May 13, 2026
Tango Therapeutics, Inc. reported a significant increase in operating losses for Q1 2026, losing $45.5 million, an increase from $39.9 million in Q1 2025. The company continued to face substantial cash burn, but remains…
Earnings analysis · 10-Q
TNGX earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, liquidity, and cash-burn trends cannot be…
Read full summary
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, liquidity, and cash-burn trends cannot be quantified from the filing content provided. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors from the 2025 Form 10-K. The filing provided no quantitative forward guidance.
What stood out
-
Disclosure Controls Remain Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No Material Litigation Identified
The company reported no material litigation proceedings that management believes are probable to adversely affect the business, and stated that it is not currently party to such proceedings.
-
Insider Trading Plan Disclosed
The filing disclosed a Rule 10b5-1 arrangement for up to 210,000 shares to be sold by the President of Research and Development, with a stated duration through October 31, 2027.
What to watch
-
Core Risk Profile Unchanged
The company stated that there have been no material changes to the risk factors in its 2025 Form 10-K filed March 5, 2026; therefore, the filing provides no evidence of reduced exposure to previously disclosed risks.
-
Additional Insider Selling Plan
A Rule 10b5-1 plan permits the Principal Accounting Officer to sell up to 68,655 shares through June 15, 2027, which could create potential share-supply and investor-perception pressure.
-
Potential Litigation Costs
The company disclosed that litigation can generate defense and settlement costs and divert management resources, even though it reported no currently material proceedings.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.